Cardiovascular Outcomes in the Outpatient Kidney Transplant Clinic
- 1 May 2008
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 3 (3) , 822-828
- https://doi.org/10.2215/cjn.00030108
Abstract
Background and objectives: Cardiovascular disease is an important cause of morbidity and death in kidney transplant recipients. This study examines the Framingham risk score9s ability to predict cardiac and stroke events. Because cyclosporine and tacrolimus have different cardiovascular risk profiles, these agents were also examined. Design, setting, participants, & measurements: A prospective cohort evaluation of 540 patients were followed for a median of 4.7 yr in an outpatient kidney transplant clinic. Baseline Framingham risk scores were calculated and all cardiovascular outcomes were collected. Results: Rates per 100 patient-years were 1.79 for cardiac and 0.78 for stroke events. The ratio of observed-to-predicted cardiac events was 1.64-fold higher [95% confidence interval (CI) 1.19 to 2.94] for the cohort, 2.74-fold higher (95% CI 1.70 to 4.24) in patients age 45 to 60 with prior cardiac disease or diabetes mellitus, but not higher in other age subgroups. Stroke was not increased above predicted. Risk scores for cardiac (c = 0.65, P = 0.003) and stroke (c = 0.71, P = 0.004) events were modest predictors. 10-yr event scores for cardiac (9.3 versus 13.5%, P < 0.001) and stroke (7.1 versus 10.0%, P = 0.002) were lower for tacrolimus compared with cyclosporine-treated patients. However observed cardiac events were higher in tacrolimus recipients (2.50, 95% CI 1.09 to 5.90) in an adjusted Cox model. Conclusions: Although risk scores are only modest predictors, patients with the highest event rates are easily identified. Treating high-risk patients with cardioprotective medications should remain a priority.Keywords
This publication has 35 references indexed in Scilit:
- β-Blockers improve outcomes in kidney disease patients having noncardiac vascular surgeryKidney International, 2007
- Strategies to reduce clinical inertia in hypertensive kidney transplant recipientsBMC Nephrology, 2007
- Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic reviewHeart, 2006
- Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac DiseaseAmerican Journal of Kidney Diseases, 2006
- An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk MarkersArchives of internal medicine (1960), 2006
- Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control GoalsHypertension, 2006
- Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failureClinical Transplantation, 2005
- Conversion from Cyclosporine to Tacrolimus Improves Quality-of-Life Indices, Renal Graft Function and Cardiovascular Risk ProfileAmerican Journal of Transplantation, 2004
- Atherosclerotic cardiovascular disease risks in chronic hemodialysis patientsKidney International, 2000
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988